Physiology and pharmacology of glucagon-like peptide-1 receptor
-
Published:2024-01-09
Issue:4
Volume:11
Page:347-380
-
ISSN:2413-2241
-
Container-title:Pharmacy & Pharmacology
-
language:
-
Short-container-title:Farm. farmakol. (Pâtigorsk)
Author:
Kurkin D. V.1ORCID, Bakulin D. A.2ORCID, Morkovin E. I.3ORCID, Petrov V. I.3ORCID, Strygin A. V.3ORCID, Koryanova K. N.4ORCID, Gorbunova Yu. V.2ORCID, Kolosov Yu. A.2ORCID, Ivanova O. V.2ORCID, Pavlova E. V.2ORCID, Dzhavakhyan M. A.2ORCID, Zaborovsky A. V.2ORCID, Saparova V. B.2ORCID, Makarenko I. E.5ORCID, Drai R. I.6ORCID, Chumachenko A. N.3ORCID
Affiliation:
1. Russian University of Medicine.
Volgograd State Medical University. 2. Russian University of Medicine 3. Volgograd State Medical University 4. Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University 5. Russian University of Medicine.
Closed joint-stock company “Farm-Holding”. 6. Closed joint-stock company “Farm-Holding”.
Abstract
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight the importance of glucagon-like peptide-1 (GLP-1) receptor agonists in the pharmacotherapy structure.The aim of the work was to review the literature regarding the physiology of GLP-1 and the therapeutic potential and development trends of its agonists.Materials and methods. The search for the review materials was carried out using the abstract databases of PubMed, Google Scholar and e-Library. The search was carried out for publications from 2000 to 2023, using the following keywords: “GLP-1”; “GLP-1R agonists”; “GIP”; “exenatide”; “liraglutide”; “dulaglutide”; “semaglutide”; “lixisenatide”; “albiglutide”; “taspoglutide” taking into account various spellings.Results. The interaction of almost all food components with enteroendocrine cells of the intestine leads to the secretion of incretins (primarily GLP-1) into the blood, triggering a complex of physiological reactions aimed primarily at the rapid utilization of incoming glucose (regulation of insulin and glucagon secretion), as well as the central regulation of dietary behavior (slowing gastric emptying and the formation of a feeling of satiety). A wide distribution of the GLP-1 receptor in various tissues and organs, its connection with intracellular signaling cascades aimed at launching energy-consuming remodeling (recovery) processes in endothelial cells, heart, neurons, beta cells, etc., is the basis for a wide range of pleiotropic effects of GLP-1 unrelated to its hypoglycemic effect. The discovery of synthetic GLP-1 receptor agonists with a long period of action has made it possible not only to therapeutically influence various parts of carbohydrate metabolism disorders, but also to increase the functional reserves of the target diabetes organs, reducing the risk of developing complications of the disease. Incretin-like drugs are well tolerated, with nausea being the most common side effect. The factors limiting a wider use of the drugs include their high cost and the preferred form of a subcutaneous solution. The current research is focused on the development of long-acting, oral, dual and triple agonists, fixed-dose combinations, and small molecule drugs.Conclusion. GLP-1 receptor agonists are a class of effective and safe drugs for the treatment of diabetes and obesity, which is rapidly developing in the most advanced areas of pharmacy. A further development of this group and the solution of the identified problems will open up new opportunities for the treatment of diabetes and its complications.
Publisher
Volgograd State Medical University
Reference120 articles.
1. Dedov II, Shestakova MV, Mayorov AYu, Mokrysheva NG, Vikulova OK, Galstyan GR, Kuraeva TL, Peterkova VA, Smirnova OM, Starostina EG, Surkova EV, Sukhareva OY, Tokmakova AY, Shamkhalova MS, Jarek-Martynova IR, Artemova EV, Beshlieva DD, Bondarenko ON, Volevodz NN, Gomova IS, Grigoryan OR, Dzhemilova ZN, Esayan RM, Ibragimova LI, Kalashnikov VY, Kononenko IV, Laptev DN, Lipatov DV, Melnikova OG, Mikhina MS, Michurova MS, Motovilin OG, Nikonova TV, Rozhivanov RV, Sklyanik IA, Shestakova EA Standards of specialized diabetes care Edited by Dedov II, Shestakova MV, Mayorov AYu 10th edition. Diabetes mellitus. 2021;24(1S):1–148. DOI: 10.14341/DM12802. Russian 2. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923–1049. DOI: 10.1016/j.eprac.2022.08.002 3. Saisho Y. Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions. Ann Transl Med. 2018;6(7):131. DOI: 10.21037/atm.2018.02.24 4. Müller TD, Finan B, Bloom SR, D’Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschöp MH. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130. DOI: 10.1016/j.molmet.2019.09.010 5. Holst JJ. From the incretin concept and the discovery of GLP-1 to today’s diabetes therapy. Front Endocrinol (Lausanne). 2019;10:260. DOI: 10.3389/fendo.2019.00260
|
|